

DECLARATION - U.S.A Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am an inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application (s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

I hereby appoint Robert Baran, Registration No. 25,806, Martin A. Voet; Registration No. 25,208; Howard R. Lambert, Registration No. 27,206, and Carlos A. Fisher, Registration No. 36,510 as attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.
SEND CORRESPONDENCE TO AND DIRECT TELEPHONE CALLS TO:

Robert J. Baran, Esq. (T2-2E)

ALLERGAN, INC.

Legal Department


2525 Dupont Drive

Irvine, CA 92612

Telephone: (714) 246-4669

Facsimile: (714) 246-4249

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF FIRST INVENTOR:			
First Name: ROBERT	Initial M.	Last Name BURK	
RESIDENCE & CITIZENSHIP			
City LAGUNA BEACH	State or Foreign Country California		Country of Citizenship United States of America
POST OFFICE ADDRESS			
Post Office Address 1337 CERRITOS DRIVE	City LAGUNA BEACH	State or Country California	Zip Code 92651
SIGNATURE OF FIRST INVENTOR 		DATE: April 16, 1999	



UNITED STATES
PATENT AND
TRADEMARK OFFICE

RECEIVED 1/7/20
APR 16 2002
LEGAL/PATENTS
RQ/1
uc
COWY
CIP

APRIL 10, 2002

PTAS

Chief Information Officer
Washington, DC 20231
www.uspto.gov

ALLERGAN, INC.
ROBERT J. BARAN
2525 DUPONT DRIVE
IRVINE, CA 92612



101983807A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/01/2002

REEL/FRAME: 012568/0465
NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
BURK, ROBERT M.

DOC DATE: 11/16/2001

ASSIGNEE:
ALLERGAN SALES, INC.
2525 DUPONT DRIVE
IRVINE, CALIFORNIA 92612

SERIAL NUMBER: 10021485
PATENT NUMBER:

FILING DATE: 10/29/2001
ISSUE DATE:

TONYA LEE, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

RJB
4/17/02

02-15-2002



101983807

FORM COVER SHEET
ENTRIES ONLY

RECEIVED

FEB 15 2002

LEGAL PATENTS

To: The Commissioner of Patents and Trademarks,

Please record the attached original document(s) or copy(ies):

FEB - 1 2002

1. Submission Type:

☒ new

2-1-02

☐ Correction of PTO error (Reel /frame)☐ Corrective Document (Reel /frame)

2. Conveyance Type:

☒ Assignment☐ License☐ Merger☐ Security Agreement☐ Change of Name☐ Other: _____

3.

CONVEYING PARTIES	
Names of Conveying Parties	Date of Conveyance
1. Robert M. Burk	November 16, 2001
2.	
3.	

☐ Additional Conveying Parties Attached

4.

RECEIVING PARTIES	
Names of Receiving Parties	
Name Allergan Sales, Inc.	
Address 1 2525 Dupont Drive	
Address 2 Irvine, CA 92612	

☐ Additional Receiving Parties Attached☐ If document is an assignment and the Receiving Party is not domiciled in the United States, an appointment of a Domestic Representative is attached

02/15/2002 LMUELLER 00000016 010885 10021485

01 FC:581

40.00 CH

5.

DOMESTIC REPRESENTATIVE NAME AND ADDRESS
Name
Address 1
Address 2

6.

CORRESPONDENCE NAME AND ADDRESS
Name Robert J. Baran (T2-7H)
Address 1 Allergan, Inc.
Address 2 2525 Dupont Drive, Irvine, CA 92612
Telephone 714-246-4669 and Fax 714-246-4249

7. Total Number of pages of the conveying document, including attachments: 4 pages

8.

APPLICATION NUMBER OR PATENT NUMBER (either; not both for same property)	
Application Number <u>10/021,485</u> ; Filed 10/29/2001	Patent Number
Application Number	Patent Number

9. If this document is being filed with a NEW patent application, enter the Docket No., Title of the Invention, and date of execution of the Assignment by the first inventor:

Title of Patent Application: _____
Docket No.: _____
Date of Execution by First Inventor: _____

10. Total Number of Properties Involved: 111. The fee amount (37 CFR §3.41) of \$ 40.00

☒ may be debited from our Deposit Account No. 01-0885.
☐ is enclosed as check no. _____.

12. ☒ The Commissioner is authorized to deduct any additional fee amounts due in connection with the filing of this document from Deposit Account No. 01-0885.

To the best of my information and belief, all statements made herein are true, and any attached copy is a true copy of the original document.

Respectfully submitted,

SIGNATURE PJ Baran Date: 1/11/02
TYPED or PRINTED NAME: Robert J. Baran. REGISTRATION NO. 25,806

CERTIFICATE OF MAILING	
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: BOX ASSIGNMENT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 ON <u>1/11/2002</u> (Date)	
Name of person making deposit: <u>Bonnie Ferguson</u>	
Signature: <u>Bonnie Ferguson</u>	Date <u>1/11/2002</u>

ASSIGNMENT

WHEREAS I, Robert M. Burk of Orange COUNTY, CALIFORNIA (hereinafter referred to as ASSIGNOR), have invented and own a certain invention entitled: CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS for which application for Letters Patent of the United States was filed on October 29, 2001 under application Serial Number 10/021,485.

WHEREAS: ALLERGAN, having its principal place of business at 2525 Dupont Drive, Irvine, CA 92612 (hereinafter referred to as ASSIGNEE), is desirous of acquiring the entire interest in, to and under said invention and in, to and under Letters Patent or similar legal protection to be obtained therefor in the United States and in any and all foreign countries.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that in consideration of the payment by ASSIGNEE TO ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE the full and exclusive right, title and interest to said invention in the United States and its territorial possessions and in all foreign countries to all Letters Patent or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for said invention by said application or any continuation, divisional, renewal, substitute or reissue thereof or any legal equivalent thereof in a foreign country for the full term or terms for which the same may be granted.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

ASSIGNOR further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said application, said invention and said Letters Patent and legal equivalents in foreign countries as may be known and accessible to ASSIGNOR and will testify as to the same in any interference or litigation related thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalent thereof in any foreign country which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this

November 16th

, 2001.

Robert M. Burk

Robert M. Burk

State of CALIFORNIA)


) ss:

County of ORANGE)

On NOVEMBER 16, 2001 before me, MARY LOU MCNOWN, Notary Public,
personally appeared ROBERT M. BURK
personally known to me (or proved to me on the basis of satisfactory evidence) to be the
person(s) whose name(s) ~~is~~ are subscribed to the within instrument and acknowledged
to me that ~~he~~ ~~she~~ ~~they~~ executed the same in his ~~her~~ ~~their~~ authorized capacity(ies), and
that by ~~his~~ ~~her~~ ~~their~~ signature(s) on the instrument the person, or the entity upon
behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Mary Lou McNown
Notary Public





UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

JUNE 30, 1997

TIMOTHY J. KING (T2-2E)
2525 DUPONT DRIVE
IRVINE, CA 92713

PTAS RECEIVED

JUL - 9 1997

100440556A

LEGAL / PATENTS

CORRECTED
NOTICE

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 05/06/1996

REEL/FRAME: 7926/0553
NUMBER OF PAGES: 12

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST. PER ATTORNEY THREE APPLICATION NUMBERS 08/527303, 08/556676 AND 08/557746 APPEAR ON THE COVERSHEET SHOULD NOT BE RECORDED. ALL OTHER NUMBERS STAND AS REQUESTED. SEE RECORD FOR DETAILS.

ASSIGNOR:
ALLERGAN, INC.

DOC DATE: 01/17/1996

ASSIGNEE:
ALLERGAN
8301 MARS DRIVE
WACO, TEXAS 76712

SERIAL NUMBER: 08496262
PATENT NUMBER:

FILING DATE: 06/28/1995
ISSUE DATE:

SERIAL NUMBER: 08437656
PATENT NUMBER: 5549670

FILING DATE: 05/09/1995
ISSUE DATE: 08/27/1996

SERIAL NUMBER: 08260648
PATENT NUMBER:

FILING DATE: 07/28/1995
ISSUE DATE:

Ernest H.

SERIAL NUMBER: 08398557
PATENT NUMBER: 5609273

FILING DATE: 03/03/1995
ISSUE DATE: 03/11/1997

SERIAL NUMBER: 08493509
PATENT NUMBER:

FILING DATE: 06/22/1995
ISSUE DATE:

SERIAL NUMBER: 08442957
PATENT NUMBER:

FILING DATE: 05/17/1995
ISSUE DATE:

SERIAL NUMBER: 08466000
PATENT NUMBER:

FILING DATE: 06/06/1995
ISSUE DATE:

SERIAL NUMBER: 08373822
PATENT NUMBER:

FILING DATE: 01/17/1995
ISSUE DATE:

SERIAL NUMBER: 08407733
PATENT NUMBER:

FILING DATE: 03/20/1995
ISSUE DATE:

SERIAL NUMBER: 08522775
PATENT NUMBER:

FILING DATE: 09/01/1995
ISSUE DATE: 08/26/1997

SERIAL NUMBER: 08377370
PATENT NUMBER:

FILING DATE: 01/23/1995
ISSUE DATE:

SERIAL NUMBER: 08379280
PATENT NUMBER:

FILING DATE: 01/27/1995
ISSUE DATE: 07/22/1997

SERIAL NUMBER: 08416101
PATENT NUMBER:

FILING DATE: 04/04/1995
ISSUE DATE: 07/15/1997

SERIAL NUMBER: 08390006
PATENT NUMBER:

FILING DATE: 02/17/1995
ISSUE DATE:

SERIAL NUMBER: 08426796
PATENT NUMBER:

FILING DATE: 04/24/1995
ISSUE DATE:

SERIAL NUMBER: 08443992
PATENT NUMBER:

FILING DATE: 05/18/1995
ISSUE DATE:

SERIAL NUMBER: 08431170
PATENT NUMBER: 5573758

FILING DATE: 04/28/1995
ISSUE DATE: 11/12/1996

SERIAL NUMBER: 08389814
PATENT NUMBER:

FILING DATE: 02/14/1995
ISSUE DATE:

SERIAL NUMBER: 08506794
PATENT NUMBER:

FILING DATE: 07/25/1995
ISSUE DATE:

SERIAL NUMBER: 08536202
PATENT NUMBER:

FILING DATE: 09/29/1995
ISSUE DATE:

SERIAL NUMBER: 08434220
PATENT NUMBER:

FILING DATE: 05/04/1995
ISSUE DATE:

SERIAL NUMBER: 08440030
PATENT NUMBER:

FILING DATE: 05/12/1995
ISSUE DATE:

SERIAL NUMBER: 08440579
PATENT NUMBER:

FILING DATE: 05/15/1995
ISSUE DATE:

SERIAL NUMBER: 08496867
PATENT NUMBER:

FILING DATE: 06/30/1995
ISSUE DATE:

SERIAL NUMBER: 08433809
PATENT NUMBER: 5624955

FILING DATE: 05/03/1995
ISSUE DATE: 04/29/1997

SERIAL NUMBER: 08511584
PATENT NUMBER:

FILING DATE: 08/04/1995
ISSUE DATE:

SERIAL NUMBER: 08510526
PATENT NUMBER:

FILING DATE: 08/02/1995
ISSUE DATE:

SERIAL NUMBER: 08522778
PATENT NUMBER:

FILING DATE: 09/01/1995
ISSUE DATE:

SERIAL NUMBER: 60005111
PATENT NUMBER:

FILING DATE: 08/08/1995
ISSUE DATE:

SERIAL NUMBER: 08512713
PATENT NUMBER:

FILING DATE: 08/08/1995
ISSUE DATE:

SERIAL NUMBER: 08522779
PATENT NUMBER:

FILING DATE: 09/01/1995
ISSUE DATE:

SERIAL NUMBER: 08528464
PATENT NUMBER:

FILING DATE: 09/12/1995
ISSUE DATE:

SERIAL NUMBER: 08540428
PATENT NUMBER: 5643276

FILING DATE: 10/10/1995
ISSUE DATE: 07/01/1997

SERIAL NUMBER: 08442223
PATENT NUMBER: 5616712

FILING DATE: 05/16/1995
ISSUE DATE: 04/01/1997

SERIAL NUMBER: 08516416
PATENT NUMBER:

FILING DATE: 08/17/1995
ISSUE DATE:

SERIAL NUMBER: 60020501
PATENT NUMBER:

FILING DATE: 10/13/1995
ISSUE DATE:

SERIAL NUMBER: 08552965
PATENT NUMBER:

FILING DATE: 11/03/1995
ISSUE DATE:

SERIAL NUMBER: 08562000
PATENT NUMBER:

FILING DATE: 11/22/1995
ISSUE DATE:

SERIAL NUMBER: 08561999
PATENT NUMBER:

FILING DATE: 11/22/1995
ISSUE DATE:

7926/0553 PAGE 4

JACQUELINE MOORE, PARALEGAL
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

APPENDIX A

Docket No.	Filed	Serial No.	Title	Inventors
16837	06/28/95	08/496,262	Method of Using (2-Imidazolin-2-Ylamino) Quinoxalines in Treating Ocular Neural Injury	Larry A. Wheeler; Elizabeth WoldeMussie; Ronald K. Lai
16867	05/09/95	08/437,656	IOL for Reducing Secondary Opacification	Craig Young; Glenn R. Sussman; Crystal M. Cunanan
17030	07/28/95	08/260,648	Method For Reducing Intraocular Pressure in the Mammalian Eye by Administration of Calcium Chelators	Joseph S. Adorante; Elizabeth WoldeMussie; Guadalupe Ruiz
17039	03/03/95	08/398,557	Barrier Packaging and Materials Therefor	Bruce A. Firestone; Matthew Dickason
17056	06/22/95	08/493,509	Method For Identifying Muscarinic Agents Lacking Miotic Side Effects	Daniel W. Gil; Elizabeth WoldeMussie
7. 17079	05/16/95	08/442,223	Acetylenes Disubstituted with a Phenyl or Heteroaryl Group and a 2-Thio-1,2,3,4-Tetrahydroquinolinyl, 2-Alkylthio-3,4-Dihydroquinolinyl or 2-Alkoxy-3,4-Dihydroquinolinyl Group Having Retinoid-Like Biological Activity	Min Teng; Richard L. Beard; Diana Colon; Tien T. Duong; Roshantha A. Chandraratna
17084	04/26/95	08/428,957	Method for Inhibiting Gene Expression Promoted by AP1 Protein With RARb Selective Retinoids and Method For Treatment of Diseases and Conditions With Such Retinoids	Sunil Nagpal; Tae K. Song; Vidyasagar Vuligonda; Jyoti Athanikar; Roshantha A. Chandraratna
17085	06/06/95	08/466,000	2,4-Pentadienoic Acid Derivatives Having Retinoid-Like Biological Activity	Vidyasagar Vuligonda; Roshantha A. Chandraratna
17093	01/17/95	08/373,822	IOL Insertion Apparatus and Method For Using Same	Shig-Liang S. Yang; Crystal M. Cunanan; Thomas M. McNicholas
17094	03/20/95	08/407,733	Method For Preventing Onset of Restenosis After Angioplasty Employing a Retinoid	Peter A. J. Davies; Roshantha A. Chandraratna; and Claude R. Benedict

APPENDIX A

Docket No.	Filed	Serial No.	Title	Inventors
17107	09/01/95	08/522,775	Method For Effecting Vasodilation With (1,5-Inter) Aryl Prostaglandin Derivatives	June Chen; Robert M. Burk; David F. Woodward
17111	01/23/95	08/377,370	Totally Liquid Fillable Collapsible Bottle and Method of Filling Same	Larry E. Branham
17114	01/27/95	08/379,280	Gene Sequence Induced in Skin by Retinoids	Sunil Nagpal; Roshantha A. Chandraratna
17115	04/04/95	08/416,101	On-Site Syringe Filling Apparatus for Viscoelastic Materials, and Corresponding Method for On-Site Syringe Filling	F. Richard Christ; Erick F. Fischer; Kenneth E. Kadziauskas
17116	02/17/95	08/390,006	Ophthalmic Compositions Including Peptides and Peptide Derivatives and Methods For Using Same	Stanley W. Huth; James P. Currie; John C. Baker
17118	04/24/95	08/426,796	Botulinum Toxin Neutralizing Antibody Detection Assay	Kei Roger Aoki; Athena Faye Spanoyannis
17120	05/18/95	08/443,992	Cyclopentane Heptan(ene)ic Acid, 2-Heteroarylalkenyl Derivatives as Therapeutic Agents	Robert M. Burk
17121	04/28/95	08/431,170	Method for Reducing Intraocular Pressure in the Mammalian Eye by Administration of Potassium Channel Blockers	Joseph S. Adorante; Elizabeth WoldeMussie; Guadalupe Ruiz
17122	02/14/95	08/389,814	Syringe and Cannula for Insertion of Viscoelastic Material Into an Eye and Method of Using Same	David Haffner
17123	07/25/95	08/506,794	Method of Vision Correction (Corneal Array)	James R. Largent
17124	09/29/95	08/536,202	Flexible Container or Bottle With Barrier Coating	James V. C. Boyles; Robert J. Demel; Crystal F. Jenkins; Orest Olejnik
17125	05/04/95	08/434,220	Nanotechnology Apparatus and Methods of Benefiting an Animal or Human Body	Timothy R. Willis

APPENDIX A

Docket No.	Filed	Serial No.	Title	Inventors
17126	05/12/95	08/440,030	Aryl-Imidazolines and Aryl-Imidazoles Useful as Alpha-2 Adrenergic Agonists Without Cardiovascular Side Effects	Stephen A. Munk; James A. Burke; Ronald K. Lai
17127	05/15/95	08/440,579	Polymer, Article and Method For Inhibiting the Growth of Ocular Pathogens in Eye Care Products	Charles H. Powell; David C. Rupp
17130	06/30/95	08/496,867	Compositions and Methods For Disinfecting A Contact Lens and Detecting the Presence of an Oxidative Disinfectant	John Y. Park; Lin Peng; Anthony J. Dziabo
17132	05/03/95	08/433,809	Compounds That Enhance the Concentration of Glutathione in Tissues	Herbert T. Nagasawa; William B. Rathbun; Jonathan F. Cohen; Michael E. Garst;
17133	08/04/95	08/511,584	Alcohol-Containing Compositions and Methods For Disinfecting	David C. Rupp; Terrence J. Hunt
17134	08/02/95	08/510,526	Instrument and Method of Measuring Torticollis	Maria Pretel; Catherine E. Hoover Elaine P. Kelley; Judith E. Leon
17135	09/01/95	08/522,778	Aryl Substituted Benzopyran, Benzothiopyran, 1, 2-Dihydroquinoline and 5, 6-Dihydronaphthalene Derivatives Having Retinoid Antagonist Like Biological Activity	Alan T. Johnson; Min Teng; Vidyasagar Vuligonda; Richard L. Beard; Samuel J. Gillett; Tien T. Duong; Roshantha A. Chandraratna
17141	08/17/95	08/516,416	Method and Composition For Controlling the Level of Adipose Tissue in a Mammal	Lidija Balodis
17142	08/08/95	60/005,111	Method of Increasing Tear Production by Topical Administration of Muramyl Peptide	Martin A. Voet
17143	08/08/95	08/512,713	Safety-Vac Capsule Polisher	Robert Z. Ziegler

APPENDIX A

Docket No.	Filed	Serial No.	Title	Inventors
17144	09/01/95	08/522,779	Use of Retinoid Antagonists to Treat Retinoid- Induced Toxicity and as an Adjunct to Therapy with Retinoids to Prevent Unwanted or Undesired Side Effects	Andrew Mark Standeven; Alan T. Johnson; Roshantha A. Chandraratna
17146	09/12/95	08/528,464	Contact Lens Care Composition Including Dicarboxylic Acid and Polymethylene Biguanide and Method of Use Thereof	Joseph E. Vigh
PROP 17147	09/12/95	08/527,303	Contact Lens Care Composition Including Dicarboxylic Acid	Joseph E. Vigh
17148	10/13/95	60/020,501	Aryl and (3-Oxo-1-Propenyl)-Substituted Benzopyran, Benzothiopyran, Dihydroquinoline and 5,6-Dihydronaphthalene Derivatives Having Retinoid Antagonist Like Biological Activity	Alan T. Johnson; Min Teng; Vidyasagar Vuligonda; Richard L. Beard; Samuel J. Gillett; Tien T. Duong; Roshantha A. Chandraratna
17149	11/01/95	08/552,965	Sulfides, Sulfoxides and Sulfones Disubstituted with a Tetrahydronaphthalenyl, Chromanyl, Thiochromanyl or Tetrahydroquinolinyl and Substituted Phenyl or Heteroaryl Group, Having Retinoid-Like Biological Activity	Richard L. Beard; Diana F. Colon; Roshantha A. Chandraratna
17150	10/10/95	08/540,428	IOL Insertion Apparatus and Method For Using Same	Edward R. Zaleski
17152	11/22/95	08/562,000	Aryl or Heteroaryl Amides of Tetrahydronaphthalene, Chroman, Thiochroman and 1,2,3,4-Tetrahydroquinoline Carboxylic Acids, Having an Electron Withdrawing Substituent in the Aromatic or Heteroaromatic Moiety, Having Retinoid-Like Biological Activity	Min Teng; Tien T. Duong; Roshantha A. Chandraratna
PROP 17154	11/13/95	08/556,676	Calcium Modulation to Control Enzymatic Contact Lens Cleaners	James N. Cook; Joseph G. Vehige; Stanley W. Huth

APPENDIX A

Docket No.	Filed	Serial No.	Title	Inventors
<i>POP</i> 17155	11/10/95	08/557,746	Multiple Tip Top Dispensing Cap	Laurie C. Grau; Wayne S. Iba
17159	11/22/95	08/561,999	Substituted Aryl or Heteroarylamides Having Retinoid-Like Biological Activity	Min Teng; Tien T. Duong; Roshantha A. Chandraratna

APPENDIX A

Docket

No.	Filed	Serial No.	Title	Inventors
16837	06/28/95	08/496,262	Method of Using (2-Imidazolin-2-Ylamino) Quinoxalines in Treating Ocular Neural Injury	Larry A. Wheeler; Elizabeth WoldeMussie; Ronald K. Lai
16867	05/09/95	08/437,656	IOL for Reducing Secondary Opacification	Craig Young; Glenn R. Sussman; Crystal M. Cunanan
17030	07/28/95	08/260,648	Method For Reducing Intraocular Pressure in the Mammalian Eye by Administration of Calcium Chelators	Joseph S. Adorante; Elizabeth WoldeMussie; Guadalupe Ruiz
17039	03/03/95	08/398,557	Barrier Packaging and Materials Therefor	Bruce A. Firestone; Matthew Dickason
17056	06/22/95	08/493,509	Method For Identifying Muscarinic Agents Lacking Miotic Side Effects	Daniel W. Gil; Elizabeth WoldeMussie
17079	05/16/95	08/442,223	Acetylenes Disubstituted with a Phenyl or Heteroaryl Group and a 2-Thio-1,2,3,4-Tetrahydroquinoliny, 2-Alkylthio-3,4-Dihydroquinoliny or 2-Alkoxy-3,4-Dihydroquinoliny Group Having Retinoid-Like Biological Activity	Min Teng; Richard L. Beard; Diana Colon; Tien T. Duong; Roshantha A. Chandraratna
17084	04/26/95	08/428,957	Method for Inhibiting Gene Expression Promoted by AP1 Protein With RARb Selective Retinoids and Method For Treatment of Diseases and Conditions With Such Retinoids	Sunil Nagpal; Tae K. Song; Vidyasagar Vuligonda; Jyoti Athanikar; Roshantha A. Chandraratna
17085	06/06/95	08/466,000	2,4-Pentadienoic Acid Derivatives Having Retinoid-Like Biological Activity	Vidyasagar Vuligonda; Roshantha A. Chandraratna
17093	01/17/95	08/373,822	IOL Insertion Apparatus and Method For Using Same	Shig-Liang S. Yang; Crystal M. Cunanan; Thomas M. McNicholas
17094	03/20/95	08/407,733	Method For Preventing Onset of Restenosis After Angioplasty Employing a Retinoid	Peter A. J. Davies; Roshantha A. Chandraratna; and Claude R. Benedict

APPENDIX A

Docket No.	Filed	Serial No.	Title	Inventors
17107	09/01/95	08/522,775	Method For Effecting Vasodilation With (1,5-Inter) Aryl Prostaglandin Derivatives	June Chen; Robert M. Burk; David F. Woodward
17111	01/23/95	08/377,370	Totally Liquid Fillable Collapsible Bottle and Method of Filling Same	Larry E. Branham
17114	01/27/95	08/379,280	Gene Sequence Induced in Skin by Retinoids	Sunil Nagpal; Roshantha A. Chandraratna
17115	04/04/95	08/416,101	On-Site Syringe Filling Apparatus for Viscoelastic Materials, and Corresponding Method for On-Site Syringe Filling	F. Richard Christ; Erick F. Fischer; Kenneth E. Kadziauskas
17116	02/17/95	08/390,006	Ophthalmic Compositions Including Peptides and Peptide Derivatives and Methods For Using Same	Stanley W. Huth; James P. Currie; John C. Baker
17118	04/24/95	08/426,796	Botulinum Toxin Neutralizing Antibody Detection Assay	Kei Roger Aoki; Athena Faye Spanoyannis
17120	05/18/95	08/443,992	Cyclopentane Heptan(ene)oic Acid, 2-Heteroarylalkenyl Derivatives as Therapeutic Agents	Robert M. Burk
17121	04/28/95	08/431,170	Method for Reducing Intraocular Pressure in the Mammalian Eye by Administration of Potassium Channel Blockers	Joseph S. Adorante; Elizabeth WoldeMussie; Guadalupe Ruiz
17122	02/14/95	08/389,814	Syringe and Cannula for Insertion of Viscoelastic Material Into an Eye and Method of Using Same	David Haffner
17123	07/25/95	08/506,794	Method of Vision Correction (Corneal Array)	James R. Largent
17124	09/29/95	08/536,202	Flexible Container or Bottle With Barrier Coating	James V. C. Boyles; Robert J. Demel; Crystal F. Jenkins; Orest Olejnik
17125	05/04/95	08/434,220	Nanotechnology Apparatus and Methods of Benefiting an Animal or Human Body	Timothy R. Willis

APPENDIX A

Docket No.	Filed	Serial No.	Title	Inventors
17126	05/12/95	08/440,030	Aryl-Imidazolines and Aryl-Imidazoles Useful as Alpha-2 Adrenergic Agonists Without Cardiovascular Side Effects	Stephen A. Munk; James A. Burke; Ronald K. Lai
17127	05/15/95	08/440,579	Polymer, Article and Method For Inhibiting the Growth of Ocular Pathogens in Eye Care Products	Charles H. Powell; David C. Rupp
17130	06/30/95	08/496,867	Compositions and Methods For Disinfecting A Contact Lens and Detecting the Presence of an Oxidative Disinfectant	John Y. Park; Lin Peng; Anthony J. Dziabo
17132	05/03/95	08/433,809	Compounds That Enhance the Concentration of Glutathione in Tissues	Herbert T. Nagasawa; William B. Rathbun; Jonathan F. Cohen; Michael E. Garst;
17133	08/04/95	08/511,584	Alcohol-Containing Compositions and Methods For Disinfecting	David C. Rupp; Terrence J. Hunt
17134	08/02/95	08/510,526	Instrument and Method of Measuring Torticollis	Maria Pretel; Catherine E. Hoover Elaine P. Kelley; Judith E. Leon
17135	09/01/95	08/522,778	Aryl Substituted Benzopyran, Benzothiopyran, 1, 2-Dihydroquinoline and 5, 6-Dihydronaphthalene Derivatives Having Retinoid Antagonist Like Biological Activity	Alan T. Johnson; Min Teng; Vidyasagar Vuligonda; Richard L. Beard; Samuel J. Gillett; Tien T. Duong; Roshantha A. Chandraratna
17141	08/17/95		Method and Composition For Controlling the Level of Adipose Tissue in a Mammal	Lidija Balodis
17142	08/08/95	60/005,111	Method of Increasing Tear Production by Topical Administration of Muramyl Peptide	Martin A. Voet
17143	08/08/95	08/512,713	Safety-Vac Capsule Polisher	Robert Z. Ziegler

APPENDIX A

Docket No.	Filed	Serial No.	Title	Inventors
17144	09/01/95	08/522,779	Use of Retinoid Antagonists to Treat Retinoid- Induced Toxicity and as an Adjunct to Therapy with Retinoids to Prevent Unwanted or Undesired Side Effects	Andrew Mark Standeven; Alan T. Johnson; Roshantha A. Chandraratna
17146	09/12/95	08/528,464	Contact Lens Care Composition Including Dicarboxylic Acid and Polymethylene Biguanide and Method of Use Thereof	Joseph E. Vigh
17147	09/12/95		Contact Lens Care Composition Including Dicarboxylic Acid	Joseph E. Vigh
17148	10/13/95		Aryl and (3-Oxo-1-Propenyl)-Substituted Benzopyran, Benzothiopyran, Dihydroquinoline and 5,6-Dihydronaphthalene Derivatives Having Retinoid Antagonist Like Biological Activity	Alan T. Johnson; Min Teng; Vidyasagar Vuligonda; Richard L. Beard; Samuel J. Gillett; Tien T. Duong; Roshantha A. Chandraratna
17149	11/01/95		Sulfides, Sulfoxides and Sulfones Disubstituted with a Tetrahydronaphthalenyl, Chromanyl, Thiochromanyl or Tetrahydroquinolinyl and Substituted Phenyl or Heteroaryl Group, Having Retinoid-Like Biological Activity	Richard L. Beard; Diana F. Colon; Roshantha A. Chandraratna
17150	10/10/95	08/540,428	IOL Insertion Apparatus and Method For Using Same	Edward R. Zaleski
17152	11/22/95		Aryl or Heteroaryl Amides of Tetrahydronaphthalene, Chroman, Thiochroman and 1,2,3,4-Tetrahydroquinoline Carboxylic Acids, Having an Electron Withdrawing Substituent in the Aromatic or Heteroaromatic Moiety, Having Retinoid-Like Biological Activity	Min Teng; Tien T. Duong; Roshantha A. Chandraratna
17154	11/13/95		Calcium Modulation to Control Enzymatic Contact Lens Cleaners	James N. Cook; Joseph G. Vehige; Stanley W. Huth

APPENDIX A

Docket No.	Filed	Serial No.	Title	Inventors
17155	11/10/95		Multiple Tip Top Dispensing Cap	Laurie C. Grau; Wayne S. Iba
17159	11/22/95		Substituted Aryl or Heteroarylamides Having Retinoid-Like Biological Activity	Min Teng; Tien T. Duong; Roshantha A. Chandraratna

06-19-1997

COR
PDEPARTMENT OF COMMERCE
Patent and Trademark Office

1996

RECEIVED
AUG 6 1996
LEGAL / PATENTS

Tab settings

100440556

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Allergan, Inc.

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☐ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other _____

Execution Date: January 17, 1996

2. Name and address of receiving party(ies):

Name: Allergan

Internal Address:

Street Address: 8301 Mars Drive

City: Waco State: TX ZIP: 76712

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: n/a

A. Patent Application No.(s)

See Attached

B. Patent No.(s)

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Timothy J. King (T2-2E)

Internal Address:

2525 Durant Drive

6. Total number of applications and patents involved:

42

7. Total fee (37 CFR 3.41): \$ 1,680.00

☒ Enclosed☐ Authorized to be charged to deposit account

ASSIGNMENT

WHEREAS: ALLERGAN, having its principal place of business at 8301 Mars Drive, Waco, Texas 76712 (hereinafter referred to as ASSIGNEE), is desirous of acquiring the entire right, title and interest in, to and under certain inventions and in, to and under corresponding Letters Patent or similar legal protection to be obtained therefor in the United States and in any and all foreign countries.

WHEREAS: ALLERGAN, INC., having its principal place of business at 2525 Dupont Drive, Irvine, California 92715 (hereinafter ASSIGNOR) owns the entire right, title and interest in, to and under certain inventions, corresponding U.S. patent applications and foreign rights directed thereto.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that in consideration of the payment by ASSIGNEE TO ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE the entire right, title and interest in, to and under certain inventions in the United States and its territorial possessions and in all foreign countries to all Letters Patents or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for certain inventions by certain applications set forth in Appendix A and any continuation, divisional, renewal, substitute or reissue thereof for the full term or terms for which the same may be granted; said sale, transfer and assignment effective January 1, 1996.

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this

JANUARY 17, 1996

Allergan, Inc.

Martin A. Voet

By: Martin A. Voet

Title: Assistant Secretary

State of CALIFORNIA)

County of ORANGE)

On JANUARY 17, 1996 before me, B.K. KICHLER, NOTARY PUBLIC personally

appeared MARTIN A. VOET personally known to me ~~or~~

~~proved to me on the basis of satisfactory evidence~~ to be the person(s) whose name(s)


is/are subscribed to the within instrument and acknowledged to me that he/she/they

executed the same in his/her/their authorized capacity(ies), and that by his/her/their

signature(s) on the instrument the person(s), or the entity upon behalf of which the

person(s) acted, executed the instrument.

WITNESS my hand and official seal.



B. K. Kichler
Notary Public



11/20
UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

OCTOBER 02, 1995

PTAS

ROBERT J. BARAN
2525 DUPONT DRIVE
IRVINE, CA 92715



100018662A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 05/18/1995

REEL/FRAME: 7506/0664
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
BURK, ROBERT M.

DOC DATE: 05/17/1995

ASSIGNEE:
ALLERGAN, INC.
2525 DUPONT DRIVE
LEGAL DEPARTMENT - T2-2E
IRVINE, CALIFORNIA 92715

SERIAL NUMBER: 08443992
PATENT NUMBER:

FILING DATE: 05/18/1995
ISSUE DATE:

JERYL MCDOWELL / EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

17120 (AP)

5-18-95

00-19-1990

CC 1

Patent and Trademark Office



027443992

Tab settings

To the Honorable Commissioner of Patents

100018662

ached original document or copy thereof.

1. Name of conveying party(ies):

Robert M. Bur



2. Name and address of receiving party(ies)

Name: Allergan, Inc.

06/15/95

Internal Address: 2525 Dupont Drive

Legal Department - T2-2E

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other

Street Address:

City: Irvine State: CA ZIP 92715

Execution Date: 5-17-95

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: 5-17-95

A. Patent Application No.(s)

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Robert J. Baran (T2-2E)

Internal Address:

Street Address: 2525 Dupont Drive

City: Irvine State: CA ZIP 92715

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41): \$ 40.00

- ☐ Enclosed
☒ Authorized to be charged to deposit account

8. Deposit account number:
01-0885

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

SB28074 06/02/95 08443992 01-0885 200 501 40.00CH

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Robert J. Baran

Name of Person Signing

RJ Baran

Signature

5/18/1995

Date

ASSIGNMENT

17120(AP)

WHEREAS I, ROBERT M. BURK of ORANGE COUNTY, CALIFORNIA, (hereinafter referred to as ASSIGNOR), have invented and own a certain invention entitled: CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS for which application for Letters Patent of the United States has been executed on even date herewith.

WHEREAS: ALLERGAN, INC. a Delaware corporation, having its principal place of business at 2525 Dupont Drive, Irvine, California 92715 (hereinafter referred to as ASSIGNEE), is desirous of acquiring the entire interest in, to and under said invention and in, to and under Letters Patent or similar legal protection to be obtained therefor in the United States and in any and all foreign countries.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that in consideration of the payment by ASSIGNEE TO ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE the full and exclusive right, title and interest to said invention in the United States and its territorial possessions and in all foreign countries to all Letters Patent or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for said invention by said application or any continuation, divisional, renewal, substitute or reissue thereof or any legal equivalent thereof in a foreign country for the full term or terms for which the same may be granted.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

ASSIGNOR further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said application, said invention and said Letters Patent and legal equivalents in foreign countries as may be known and accessible to ASSIGNOR and will testify as to the same in any interference or litigation related thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalent thereof in any foreign country which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this

May 17, 1995

Robert M. Burk

ROBERT M. BURK

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

No. 5907

State of CALIFORNIA

County of ORANGE

On MAY 17 1995, before me, MARY LOU MC NOWN, a notary public
DATE NAME, TITLE OF OFFICER - E.G., "JANE DOE, NOTARY PUBLIC"

personally appeared ROBERT M. BURK
NAME(S) OF SIGNER(S)

☒ personally known to me - OR - ☐ proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) ~~is~~ are subscribed to the within instrument and acknowledged to me that ~~he~~ she/they executed the same in ~~his~~ her/their authorized capacity(ies), and that by ~~his~~ her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



WITNESS my hand and official seal.

Mary Lou Mc Now
SIGNATURE OF NOTARY

OPTIONAL

Though the data below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent reattachment of this form.

CAPACITY CLAIMED BY SIGNER

☒ INDIVIDUAL
☐ CORPORATE OFFICER

TITLE(S)

☐ PARTNER(S) ☐ LIMITED
☐ GENERAL
☐ ATTORNEY-IN-FACT
☐ TRUSTEE(S)
☐ GUARDIAN/CONSERVATOR
☐ OTHER: _____

SIGNER IS REPRESENTING:
NAME OF PERSON(S) OR ENTITY(IES)

DESCRIPTION OF ATTACHED DOCUMENT

17120-AP
U.S. Patent Assignment
TITLE OR TYPE OF DOCUMENT

1
NUMBER OF PAGES

MAY 17 1995
DATE OF DOCUMENT

N/A
SIGNER(S) OTHER THAN NAMED ABOVE

#5

Rec'd in USPTO PTO Office. Date Stamp and Return Card.

Date: April 8, 2003

Serial No.: 379 - See attached Appendix "A"

Title: 379 - See attached

Dkt. No.: Appendix "A"

Enclosed Are:

- ☐ Specification # _____, Claims # _____, and Abstract # _____
- ☐ Drawings (____ sheets)
____ Formal ____ Informal
- ☐ Info. Disc. Statement
- ☐ Priority Documents # _____
- ☐ PTO 1449 W/References
- ☐ PCT Request (# pgs. _____)
- ☐ PCT Demand (# pgs. _____)
- ☐ PCT Response (# pgs. _____)
- ☐ PCT Amendment (# pgs. _____)

- ☐ Declaration, Power of Attorney
- ☒ Assignment & Cover Sheet
(covering 379 patents)
Amendment (Final) (# pgs. _____)
- ☐ Certificate of Mailing
- ☐ Issue Fee Transmittal
- ☐ Transmittal Letter
- ☐ Extension of Time
- ☐ Express Mail No. _____
- (Assignment for Issued Vision Pharmaceuticals L.P. (Allergan) patents to ALLERGAN, INC. Certif. Under 37 CFR 1.10)

Rec'd in USPTO PTO Office. Date Stamp and Return Card.

Date: April 8, 2003

Serial No.: 379 - See attached Appendix "A"

Title: 379 - See attached

Dkt. No.: Appendix "A"

Enclosed Are:

- ☐ Specification # _____, Claims # _____, and Abstract # _____
- ☐ Drawings (____ sheets)
____ Formal ____ Informal
- ☐ Info. Disc. Statement
- ☐ Priority Documents # _____
- ☐ PTO 1449 W/References
- ☐ PCT Request (# pgs. _____)
- ☐ PCT Demand (# pgs. _____)
- ☐ PCT Response (# pgs. _____)
- ☐ PCT Amendment (# pgs. _____)

- ☐ Declaration, Power of Attorney
- ☒ Assignment & Cover Sheet
(covering 379 patents)
Amendment (Final) (# pgs. _____)
- ☐ Certificate of Mailing
- ☐ Issue Fee Transmittal
- ☐ Transmittal Letter
- ☐ Extension of Time
- ☐ Express Mail No. _____
- (Assignment for Issued Vision Pharmaceuticals L.P. (Allergan) patents to ALLERGAN, INC. Certif. Under 37 CFR 1.10)

RECEIVED

APR 28 2003

LEGAL/PATENT

RECORDATION FORM COVER SHEET PATENTS ONLY

To: The Commissioner of Patents and Trademarks,

Please record the attached original document(s) or copy(ies):

1. Submission Type:

☒ new

☐ Correction of PTO error (Reel /frame)

☐ Corrective Document (Reel /frame)

2. Conveyance Type:

☒ Assignment

☐ License

☐ Merger

☐ Security Agreement

☐ Change of Name

☐ Other: _____

3.

CONVEYING PARTIES	
Names of Conveying Parties	Date of Conveyance
1. Allergan Sales, LLC (formerly in the name of Vision Pharmaceuticals L.P. or	April 4, 2003
2. Allergan - with Waco or Dupont address)	
3.	

☐ Additional Conveying Parties Attached

4.

RECEIVING PARTIES
Names of Receiving Parties
Name Allergan, Inc.
Address 1 2525 Dupont Drive
Address 2 Irvine, CA 92612

☐ Additional Receiving Parties Attached

☐ If document is an assignment and the Receiving Party is not domiciled in the United States, an appointment of a Domestic Representative is attached.

5.

DOMESTIC REPRESENTATIVE NAME AND ADDRESS
Name
Address 1
Address 2

6.

CORRESPONDENCE NAME AND ADDRESS
Name Martin A. Voet (T2-7H)
Address 1 Allergan, Inc.
Address 2 2525 Dupont Drive, Irvine, CA 92612
Telephone 714-246-5894 and Fax 714-246-4249

7. Total Number of pages of the conveying document, including attachments: 41 pages

8.

APPLICATION NUMBER OR PATENT NUMBER (either; not both for same property)	
Application Number <u>see attached Appendix A</u>	Patent Number
Application Number	Patent Number

9. If this document is being filed with a NEW patent application, enter the Docket No., Title of the Invention, and date of execution of the Assignment by the first inventor:

Title of Patent Application: _____
 Docket No.: _____
 Date of Execution by First Inventor: _____

10. Total Number of Properties Involved: 37911. The fee amount (37 CFR §3.41) of \$ 15,160


☒ may be debited from our Deposit Account No. 01-0885.
☐ is enclosed as check no. _____.

12. ☒ The Commissioner is authorized to deduct any additional fee amounts due in connection with the filing of this document from Deposit Account No. 01-0885.

To the best of my information and belief, all statements made herein are true, and any attached copy is a true copy of the original document.


Respectfully submitted,

SIGNATURE

Date: 4/17/2003TYPED or PRINTED NAME: Martin A. Voet. REGISTRATION NO. 25,208

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: BOX ASSIGNMENT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 ON April 8, 2003 (Date)

Name of person making deposit: Mary Lou McNowenSignature:  Date: April 8, 2003

ASSIGNMENT OF ISSUED U.S. PATENTS

WHEREAS: ALLERGAN, INC., a Delaware corporation, having its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (hereinafter referred to as ASSIGNEE), is desirous of acquiring the entire right, title and interest in, to and under certain inventions and in, to and under corresponding Letters Patent obtained in the United States.

WHEREAS: On April 19, 1995, as a result of an internal domestic restructure, Allergan, Inc. formed a Texas limited partnership called VISION PHARMACEUTICALS L.P. (copy attached). On April 20, 1995, VISION PHARMACEUTICALS L.P. filed an Assumed Name Certificate for the name ALLERGAN (copy attached). Assignments were filed using VISION PHARMACEUTICALS L.P., with an address of 8301 Mars Drive, Waco, TX 76712 or ALLERGAN (with either the Waco address or 2525 Dupont Drive, Irvine, CA).

WHEREAS: VISION PHARMACEUTICALS L.P. was a limited partner to Pacific Vision, Limited, Inc., L.P., also a limited partner, and Allergan General, Inc. which was the general partner. The three partners were wholly owned subsidiaries of Allergan Sales, Inc., which assumed all of the assets and liabilities of the three partners, merged Pacific Vision Limited, Inc., L.P. (Exhibit "A") and Allergan General, Inc. (Exhibit "B") into itself and cancelled VISION PHARMACEUTICALS L.P. (Exhibit "C"). Effective June 3, 2002, ALLERGAN SALES, INC. was merged into ALLERGAN SALES, LLC (Exhibit "D").

WHEREAS: ALLERGAN SALES, LLC, having its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (hereinafter ASSIGNOR) by virtue of the above-mentioned cancellation and merger owns the entire right, title and interest in, to and under to certain U.S. Letters Patents.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that in consideration of the payment by ASSIGNEE TO ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE the entire right, title and interest in, to and under certain inventions and corresponding United States Letters Patents set forth in Appendix "A" and any continuation, divisional, renewal, substitute or reissue thereof for the full term or terms for which the same may be granted. ASSIGNOR further sells, transfers and assigns to ASSIGNEE the right to recover past damages for infringing one or more of such patents, such damages having accrued while one or more of such patents was owned by ASSIGNOR.

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this 8 day of April 2003.

ALLERGAN SALES, LLC

By:

Martin A. Voet


Martin A. Voet

Assistant Secretary

State of CALIFORNIA)
(ss.
County of ORANGE)

On April 8, 2003, before me, Mary Lou McNown, notary public, personally appeared MARTIN A. VOET personally known to me to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.



Mary Lou McNown
Signature of Notary Public

APPENDIX "A" (Page 1)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
D 279,357	David W. Mitchell	14167 Design
4,786,651	Larry Wheeler	16505
4,725,620	Garst, et al.	16518
4,739,098	R. A. Chandraratna	16519
4,923,884	R. A. Chandraratna	16553-FWC
4,927,947	R. A. Chandraratna	16553-DIV1
4,980,484	R. A. Chandraratna	16553-DIV2
4,981,841	David R. Gibson	16557-DIV2
5,246,962	R. A. Chandraratna	16560-DIV1
5,354,776	R. A. Chandraratna	16560-DIV2
5,466,690	R. A. Chandraratna	16560-DIV3
5,089,509	R. A. Chandraratna	16561-CIP1
5,354,752	R. A. Chandraratna	16561-DIV2- CIP-CON
5,677,451	R. A. Chandraratna	16561-DIV2- CIP2
5,348,972	R. A. Chandraratna	16561-CIP-DIV3
5,380,877	R. A. Chandraratna	16561-CIP-DIV4
5,234,926	R. A. Chandraratna	16561-CIP-DIV
5,663,347	R. A. Chandraratna	16561-DIV3- CIP2
5,602,130	R. A. Chandraratna	16561-CIP-DIV4 -CIP
5,264,578	R. A. Chandraratna	16561-CIP-DIV2
5,468,879	R. A. Chandraratna	16561-DIV-CIP2
6,344,463	R. A. Chandraratna	16561-CIP3- DIV5
5,750,693	R. A. Chandraratna	16561-CIP3- DIV3
6,090,826	R. A. Chandraratna	16561-CIP3- DIV4
4,810,804	R. A. Chandraratna	16562
5,134,128	Gary C. M. Lee	16564-CIP
RE 33,997	Kuzma; et al.	16578-Reissue
5,231,113	Chandraratna; et al.	16639-CON-DIV
5,130,335	Candraratna; et al.	16639-CON
4,895,868	R. A. Chandraratna	16640
5,015,658	R. A. Chandraratna	16640-CIP
4,935,530	Gary C. M. Lee	16645
5,089,485	Gary C. M. Lee	16647-CIP
5,059,611	Gary C. M. Lee	16648-CIP
4,957,917	Gary C. M. Lee	16649-CIP
5,424,078	Dziabo; et al.	16651-CIP

APPENDIX "A" (Page 2)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
5,045,564	Gary C. M. Lee	16652-CIP
5,376,676	Gary C. M. Lee	16652-CIP2
5,399,573	Garner; et al.	16654-FWC2-CIP
5,589,464	Garner; et al.	16654-FWC2-CIP-DIV
Des 315,164	Ryder	16740-Design
5,281,591	James A. Burke	16744-CIP-DIV
5,180,721	James A. Burke	16744-CIP
5,574,066	Ming F. Chan; et al.	16750-CON2-FWC
5,310,571	David Meadows	16752
5,028,624	Chan; et al.	16755-FWC
5,446,041	Chan; et al.	16756-FWC
4,992,468	R. A. Chandraratna	16757
5,068,252	R. A. Chandraratna	16757-DIV
5,034,413	Chan; et al.	16758-FWC
5,034,406	Charles Gluchowski	16760
5,077,292	Charles Gluchowski	16761
5,204,347	Charles Gluchowski	16761-DIV
5,198,442	Charles Gluchowski	16761-DIV-CIP
5,300,504	Charles Gluchowski	16761-DIV2
5,112,822	Charles Gluchowski	16761-CIP
5,231,096	Charles Gluchowski	16761-CIP2
5,326,763	Charles Gluchowski	16761-CIP2-DIV
5,373,010	Charles Gluchowski	16761-CIP2-DIV2
5,418,234	Gluchowski; et al.	16761-CIP2-DIV3
5,093,329	David F. Woodward	16763
5,183,827	R. A. Chandraratna	16764-DIV
5,272,156	R. A. Chandraratna	16764-DIV2
5,045,551	R. A. Chandraratna	16764
5,407,937	R. A. Chandraratna	16764-DIV3
5,534,516	R. A. Chandraratna	16764-DIV4
5,599,819	R. A. Chandraratna	16764-DIV5
5,616,597	R. A. Chandraratna	16764-DIV6
5,677,323	R. A. Chandraratna	16764-DIV6-DIV
4,980,369	R. A. Chandraratna	16765
5,162,546	R. A. Chandraratna	16765-CIP-DIV
5,278,318	R. A. Chandraratna	16765-CIP-DIV2
5,023,341	R. A. Chandraratna	16766
5,053,523	R. A. Chandraratna	16766-DIV
5,717,094	R. A. Chandraratna	16766-DIV2
5,248,777	R. A. Chandraratna	16766-DIV3
5,279,673	Dziabo; et al.	16767

APPENDIX "A" (Page 3)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
5,171,526	Wong; et al.	16771
5,145,643	Dziabo; et al.	16772
5,277,901	Vigh; et al.	16772-CIP
5,451,398	Vigh; et al.	16772-CIP2
5,011,856	David F. Woodward	16775
5,194,449	David F. Woodward	16775-DIV
5,112,853	Garst; et al.	16777-CON
5,258,400	Garst; et al.	16777-CON-DIV
5,021,416	Charles Gluchowski	16779
5,055,467	Pamela Albaugh	16784
5,198,545	Pamela Albaugh	16784-CON
5,264,449	Pamela Albaugh	16785
5,453,434	Albaugh; et al.	16785-DIV2-CIP
4,702,865	Koziol; et al.	16787
5,013,744	R. A. Chandraratna	16796
5,175,185	R. A. Chandraratna	16796-DIV
5,264,456	R. A. Chandraratna	16796-DIV2
5,414,007	R. A. Chandraratna	16796-DIV3
5,516,904	R. A. Chandraratna	16796-DIV4
5,013,744	R. A. Chandraratna	16796-Re-Exam
5,006,550	R. A. Chandraratna	16797
5,215,991	James A. Burke	16798-CIP
5,627,162	Gwon; et al.	16799-FWC
5,130,441	Charles Gluchowski	16801
5,237,072	Charles Gluchowski	16801-DIV
5,202,471	R. A. Chandraratna	16808
5,349,105	R. A. Chandraratna	16808-CON
5,066,664	Charles Gluchowski	16809
5,252,595	Charles Gluchowski	16812-DIV
5,151,440	Charles Gluchowski	16812
5,252,318	Joshi; et al.	16813
5,441,732	Hoeg; et al.	16813-CIP
5,081,147	Gary C. M. Lee	16814
5,212,172	Gary C. M. Lee	16814-DIV
5,081,261	Gary C. M. Lee	16815
5,013,850	Gary C. M. Lee	16819
5,474,780	James N. Chang	16820-CIP
5,238,961	Woodward; et al.	16822
5,037,811	Gary C. M. Lee	16823
5,043,457	Gary C. M. Lee	16824
5,173,298	David L. Meadows	16826
5,518,731	David L. Meadows	16826-CIP-FWC
5,620,699	David L. Meadows	16826-CIP-FWC-DIV

APPENDIX "A" (Pag 4)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
6,458,376	David L. Meadows	16826-DIV-CIP
5,139,491	Chan; et al.	16829
5,323,775	Joshi; et al.	16831
5,634,458	Joshi; et al.	16831-DIV
5,707,614	Joshi; et al.	16831-DIV2
5,296,228	Chang; et al.	16834
5,275,820	Nienyuan J. Chang	16835
5,276,044	Ambrus; et al.	16836
5,856,329	Wheeler; et al.	16837
5,091,528	Charles Gluchowski	16838
5,270,049	Chan; et al.	16841
5,183,906	Lee; et al.	16845
5,225,571	Gary C. M. Lee	16846
5,169,963	Gary C. M. Lee	16847
5,171,864	Gary C. M. Lee	16848
5,262,437	Ming Fai Chan	16851-CIP
5,312,832	Ming Fai Chan	16854
5,288,754	Woodward; et al.	16855
5,346,915	R. A. Chandraratna	16856-CON
6,136,850	Park; et al.	16859
5,082,954	Lee; et al.	16864-CIP
5,171,863	Lee; et al.	16864-DIV
5,322,953	Lee; et al.	16864-DIV2
5,298,633	Lee; et al.	16864-DIV3
5,292,517	Nienyuan J. Chang	16868
5,455,265	R. A. Chandraratna	16873
5,134,159	R. A. Chandraratna	16877
5,324,744	R. A. Chandraratna	16877-DIV
5,348,975	R. A. Chandraratna	16877-DIV2
5,346,895	R. A. Chandraratna	16879-CON
6,395,277	Herbert K. Graham	16897
5,197,638	Robert Wood	16898
5,658,948	Jasmin C. Lucero	16915-CIP
5,767,154	Woodward; et al.	16917-CIP
5,252,246	Ding; et al.	16899
5,518,718	Ding; et al.	16899-DIV-CON
5,462,968	David F. Woodward	16925
5,698,598	David F. Woodward	16925-CIP
5,326,898	R. A. Chandraratna	16926
5,434,173	R. A. Chandraratna	16927-DIV
5,391,753	R. A. Chandraratna	16927-CON
5,716,952	WoldeMussie; et al.	16931
5,420,295	Garst; et al.	16936

APPENDIX "A" (Page 5)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
5,519,150	Garst; et al.	16936-DIV
5,268,387	Michael E. Garst	16937
5,387,606	Michael E. Garst	16937-DIV
5,541,221	Michael E. Garst	16937-DIV2
5,387,394	John C. Baker	16942-FWC
5,178,635	Gwon; et al.	16943
5,300,114	Gwon; et al.	16943-DIV
5,324,840	R. A. Chandraratna	16945
5,475,113	R. A. Chandraratna	16945-CIP
5,385,945	Garst; et al.	16951
5,674,910	Garst; et al.	16951-DIV2
5,552,434	Garst; et al.	16951-DIV
5,773,654	Garst; et al.	16951-DIV2-DIV
5,300,499	Ken Chow	16953
5,352,708	Woodward; et al.	16955
5,607,978	Woodward; et al.	16955-DIV-CON
5,688,819	Woodward; et al.	16955-DIV-CON- CIP
6,403,649	Woodward; et al.	16955-DIV-CON- CIP-CON2
5,332,730	Ming F. Chan	16956
5,312,842	Ming F. Chan	16957
5,733,938	Olejnisk; et al.	16958
5,468,778	Garst; et al.	16959
5,328,933	Ming F. Chan	16960
6,124,353	David F. Woodward	16969
5,696,162	R. A. Chandraratna	16970-DIV
5,602,135	R. A. Chandraratna	16970-DIV2
5,677,320	R. A. Chandraratna	16970-DIV3
5,344,959	R. A. Chandraratna	16971
5,426,118	Chandraratna; et al.	16972
5,618,836	Chandraratna; et al.	16972-DIV
5,451,605	Chandraratna; et al.	16973
5,470,999	Chandraratna; et al.	16974
5,399,561	R. A. Chandraratna	16977
5,556,996	Beard; et al.	16978
6,338,847	Larry K. Thomas	16981-FWC
5,451,686	Michael E. Garst	16982
5,561,132	Burke; et al.	16986-FWC
5,552,403	Burke; et al.	16986-DIV
5,587,376	Burke; et al.	16986-FWC-DIV2
5,756,503	Burke; et al.	16986-FWC-DIV3
5,714,486	Burke; et al.	16986-FWC-DIV4
5,703,077	Burke; et al.	16986-FWC-DIV5

APPENDIX "A" (Pag 6)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
5,773,440	Burke; et al.	16986-FWC-DIV6
6,323,204	Burke; et al.	16986-FWC-DIV3a-CIP
5,399,586	Davies; et al. (only that portion assigned to Allergan Waco)	16988
6,057,433	Gil; et al. (only that portion assigned to Allergan Waco)	16989
6,197,933	Gil; et al. (only that portion assigned to Allergan Waco)	16989-DIV
5,416,106	Burk; et al.	16990
5,741,812	Burk; et al.	16990-DIV-CIP2
5,650,431	Burk; et al.	16990-DIV-CIP
5,516,791	Burk; et al.	16990-DIV1
6,462,077	Burk; et al.	16990-DIV-CIP2-CON2-CIP
5,369,127	Burk; et al.	16991
5,654,329	Burk; et al.	16991-CIP-DIV
5,714,621	Burk; et al.	16991-CIP-DIV2
5,808,101	Burk; et al.	16991-CIP2-DIV
5,814,657	Burk; et al.	16991-CIP-CON-DIV
5,874,460	Burk; et al.	16991-CIP-CON-DIV2
5,710,288	Burk; et al.	16991-CIP2
5,523,296	Burk; et al.	16991-CIP
5,387,608	Steven W. Andrews	16992
5,457,131	Steven W. Andrews	16992-DIV
5,736,165	Ripley; et al.	16997-CIP
6,024,954	Park; et al.	16997-CIP3
5,648,074	Park; et al.	16997-CIP2
5,656,635	Ming Fai Chan	17001
5,545,665	Robert M. Burk	17008
5,587,391	Robert M. Burk	17008-DIV
5,681,848	Robert M. Burk	17008-DIV2
5,798,378	Robert M. Burk	17008-DIV3
5,906,989	Robert M. Burk	17008-DIV4
5,990,138	Robert M. Burk	17008-DIV5
6,303,658	Robert M. Burk	17008-DIV5-CON
6,414,022	Robert M. Burk	17008-DIV5-CON2

APPENDIX "A" (Page 7)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
5,580,892	Garst; et al.	17014
5,708,015	Garst; et al.	17014-DIV
5,476,872	Garst; et al.	17018
5,474,979	Ding; et al.	17025
5,981,607	Ding; et al.	17025-CIP2
5,564,596	Meadows; et al.	17026-FWC
5,891,911	Adorante; et al.	17030
5,534,641	Song; et al.	17031
5,698,700	Song; et al.	17031-DIV
5,847,160	Song; et al.	17031-DIV2
5,519,040	Chow; et al.	17035
5,498,795	Song; et al.	17036
5,799,837	Firestone; et al.	17039-CIP
5,731,337	Munk; et al.	17053-FWC
6,150,389	Munk; et al.	17053-FWC-CIP
6,319,935	Munk; et al.	17053-FWC-CIP- CON
5,677,327	Gil; et al.	17056
5,521,183	Woodward; et al.	17057
5,659,042	Gillett; et al.	17059
5,616,712	Teng; et al.	17079
5,602,143	Achim H. Krauss	17081
5,652,236	Achim H. Krauss	17081-CIP
5,559,151	Adorante; et al.	17082
5,705,530	Adorante; et al.	17082-CON
5,866,605	Adorante; et al.	17082-CON2
5,824,685	Campochiaro; et al.	17083
	(only that portion assigned to Allergan Waco)	
6,071,924	Campochiaro; et al.	17083-CON
	(only that portion assigned to Allergan Waco)	
6,075,032	Campochiaro; et al.	17083-CIP
	(only that portion assigned to Allergan Waco)	
6,372,753	Campochiaro; et al.	17083-CIP-CON
	(only that portion assigned to Allergan Waco)	
6,025,388	Nagpal; et al.	17084
6,369,100	Nagpal; et al.	17084-DIV
5,675,033	Vuligonda; et al.	17085
5,917,082	Vuligonda; et al.	17085-CIP
5,663,367	Vuligonda; et al.	17085-DIV2

APPENDIX "A" (Page 8)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
5,780,647	Vuligonda; et al.	17085-DIV-FWC
6,034,242	Vuligonda; et al.	17085-DIV2-DIV-DIV
6,114,533	Vuligonda; et al.	17085-DIV2-DIV-DIV-CON
6,313,163	Vuligonda; et al.	17085-DIV4-CON-CON
5,798,372	Davies; et al.	17094-FWC
	(only that portion assigned to Allergan Waco)	
5,543,534	Vuligonda; et al.	17096
5,723,620	Vuligonda; et al.	17096-DIV
5,654,469	Vuligonda; et al.	17096-DIV2
5,618,943	Vuligonda; et al.	17097
5,514,825	Vuligonda; et al.	17098
5,591,858	Vuligonda; et al.	17098-DIV
5,599,967	Vuligonda; et al.	17099
5,648,503	Vuligonda; et al.	17099-DIV
5,605,915	Vuligonda; et al.	17099-DIV2
5,489,584	Vuligonda; et al.	17100
5,618,931	Beard; et al.	17101
5,648,514	Johnson; et al.	17102
5,808,083	Johnson; et al.	17102-DIV
5,998,471	Johnson; et al.	17102-DIV2
6,355,806	Johnson; et al.	17102-DIV3
5,661,178	Chen; et al.	17107
5,750,784	Chen; et al.	17107-CON
5,650,279	Nagpal; et al.	17114
5,731,161	Aoki; et al.	17118
5,834,498	Robert M. Burk	17120-FWC
5,972,991	Robert M. Burk	17120-FWC-CON
6,037,364	Robert M. Burk	17120-FWC-CON2
6,204,287	Robert M. Burk	17120-FWC-CON3
6,310,087	Robert M. Burk	17120-FWC-CON4
5,573,758	Adorante; et al.	17121
5,925,342	Adorante; et al.	17121-CON2
6,087,361	Munk; et al.	17126-CIP2
5,739,178	Powell; et al.	17127
5,854,303	Powell; et al.	17127-DIV
D430,296	Pretel; et al.	17128 Design
D379,657	Pretel; et al.	17129 Design
5,845,638	Pretel; et al.	17134
5,965,621	Lidija Balodis	17141-CIP

APPENDIX "A" (Page 9)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
5,672,710	Beard; et al.	17149
5,675,024	Teng; et al.	17152
5,856,490	Teng; et al.	17152-DIV
6,034,244	Teng; et al.	17152-DIV2
6,124,455	Teng; et al.	17152-DIV3
5,663,357	Teng; et al.	17159
5,917,048	Teng; et al.	17159-DIV
6,051,713	Teng; et al.	17159-DIV2
6,245,786	Teng; et al.	17159-DIV3
6,320,047	Teng; et al.	17159-DIV4
6,437,129	Teng; et al.	17159-DIV5
5,238,153	Castillo; et al.	17164
5,741,810	Robert M. Burk	17169
6,096,902	Robert M. Burk	17169-CON
5,965,606	Teng; et al.	17170
6,534,544	Teng; et al.	17170-DIV1
5,776,699	Klein; et al.	17171
5,952,345	Klein; et al.	17171-DIV
5,958,954	Klein; et al.	17171-DIV-CIP
5,877,207	Klein; et al.	17171-CIP
6,090,810	Klein; et al.	17171-DIV2
6,521,624	Klein; et al.	17171-DIV2-DIV
6,008,204	Klein; et al.	17171-DIV3
6,228,848	Klein; et al.	17171-DIV4
6,218,128	Klein; et al.	17171-CIP4
6,469,028	Klein; et al.	17171-DIV5
5,688,957	Teng; et al.	17173
5,721,215	Aoki; et al.	17177
5,658,897	Robert M. Burk	17182
6,258,844	Garst; et al.	17184
5,739,338	Beard; et al.	17187
5,741,896	Vuligonda; et al.	17193
6,051,731	Vuligonda; et al.	17193-DIV
6,187,933	Vuligonda; et al.	17193-DIV2
6,344,561	Vuligonda; et al.	17193-DIV3
6,465,663	Vuligonda; et al.	17193-DIV4
5,747,542	Vuligonda; et al.	17194
5,763,635	Vuligonda; et al.	17195
5,998,655	Vuligonda; et al.	17195-DIV
5,723,666	Vuligonda; et al.	17196
5,808,124	Beard; et al.	17197
5,773,594	Johnson; et al.	17198
6,117,987	Johnson; et al.	17198-DIV
5,675,019	Dolly; et al.	17200

APPENDIX "A" (Pag 10)

<u>PATENT NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
5,675,038	Dolly; et al.	17201
5,759,218	Martin; et al.	17210
6,037,488	Song; et al.	17213
6,235,923	Song; et al.	17213-DIV2
6,225,494	Song; et al.	17213-DIV
5,919,970	Song; et al.	17214
6,187,950	Song; et al.	17214-DIV
6,455,701	Song; et al.	17214-DIV2
5,728,846	Vuligonda; et al.	17218
6,087,505	Vuligonda; et al.	17218-DIV
Intf 104,803	Vuligonda; et al.	17218-DIV2
		Interference
5,922,746	Joseph S. Adorante	17219
5,760,276	Beard; et al.	17220
5,776,687	Nagpal; et al.	17223
6,294,657	Nagpal; et al.	17223-CON
6,017,953	Burk; et al.	17225
6,090,845	Burk; et al.	17225-CON
6,074,661	Olejnuk; et al.	17237-CON
6,110,485	Olejnuk; et al.	17237-CON2
6,124,344	Robert M. Burk	17244
6,160,129	Robert M. Burk	17244-CON
6,248,773	Robert M. Burk	17244-CON-
		CPA-CON
5,877,211	David F. Woodward	17245
6,090,847	David F. Woodward	17245-CON
6,034,110	Nagpal; et al.	17250
6,291,466	Gwon; et al.	17267



The State of Texas


SECRETARY OF STATE

IT IS HEREBY CERTIFIED, that
VISION PHARMACEUTICALS L.P.


filed a certificate of limited partnership in this office on

APRIL 19, 1995;

IT IS HEREBY FURTHER CERTIFIED, that
no cancellation has been filed for said partnership.



IN TESTIMONY WHEREOF, I have hereunto
signed my name officially and caused to be
impressed hereon the Seal of State at my office in
the City of Austin, on June 17, 1996.



Antonio O. Garza, Jr.
Secretary of State

PH



The State of Texas

SECRETARY OF STATE

The undersigned, as Secretary of State of the State of Texas, **HEREBY CERTIFIES** that the attached is a true and correct copy of the following described instruments on file in this office:

VISION PHARMACEUTICALS L.P.
ASSUMED NAME: ALLERGAN

ASSUMED NAME CERTIFICATE

APRIL 20, 1995



IN TESTIMONY WHEREOF, I have hereunto signed my name officially and caused to be impressed hereon the Seal of State at my office in the City of Austin, on February 21, 1997.

1077.

Antonio O. Garza, Jr.
Secretary of State

BAM



FILED
In the Office of the
Secretary of State of Texas

APR 20 1995


Corporations Section

ASSUMED NAME CERTIFICATE

1. The name of the corporation, limited liability company, limited partnership, or registered limited liability partnership as stated in its articles of incorporation, articles of organization, certificate of limited partnership, application or comparable document is VISION PHARMACEUTICALS L.P.
2. The assumed name under which the business or professional service is or is to be conducted or rendered is ALLERGAN
3. The state, country, or other jurisdiction under the laws of which it was incorporated, organized or associated is Texas, and the address of its registered or similar office in that jurisdiction is 400 North St. Paul, Dallas, Texas 75201
4. The period, not to exceed 10 years, during which the assumed name will be used is 10 years
5. The entity is a (circle one): business corporation, non-profit corporation, professional corporation, professional association, limited liability company, limited partnership, registered limited liability partnership or some other type of incorporated business, professional or other association (specify) _____
6. If the entity is required to maintain a registered office in Texas, the address of the registered office is 400 North St. Paul, Dallas, Texas 75201 and the name of its registered agent at such address is Prentice-Hall Corporation System, Inc.. The address of the principal office (if not the same as the registered office) is 8301 Mars Drive, Waco, Texas 76712
7. If the entity is not required to or does not maintain a registered office in Texas, the office address in Texas is N/A and if the entity is not incorporated, organized or associated under the laws of Texas, the address of its place of business in Texas is N/A and the office address elsewhere is _____
8. The county or counties where business or professional services are being or are to be conducted or rendered under such assumed name are (if applicable, use the designation "ALL" or "ALL EXCEPT"):
"All"

Exhibit A

member of VPLP
limited partner into
Allergon Sales, Inc.
California/Delaware




SECRETARY OF STATE

I, **BILL JONES**, Secretary of State of the State of California,
hereby certify:

That the attached transcript of 2 page(s) has
been compared with the record on file in this office, of
which it purports to be a copy, and that it is full, true
and correct.

IN WITNESS WHEREOF, I execute this
certificate and affix the Great Seal of
the State of California this day of

DEC 29 1998



Bill Jones

Secretary of State

CERTIFICATE OF OWNERSHIP

MERGING

PACIFIC VISION LIMITED, INC.

INTO

ALLERGAN SALES, INC.

ENDORSED
FILEDIn the office of the Secretary of State
of the State of California

DEC 15 1998

Bill Jones
BILL JONES, Secretary of State

F. Michael Ball and Francis R. Tunney, Jr. hereby certify that:

1. They are the president and secretary, respectively, of Allergan Sales, Inc., a California corporation (the "Corporation").
2. The Corporation owns one hundred percent (100%) of the outstanding shares of Pacific Vision Limited, Inc., a Delaware corporation.
3. The Corporation hereby merges Pacific Vision Limited, Inc. into the Corporation, effective for purposes of the General Corporation Law of the State of Delaware and the General Corporation Law of the State of California at 11:59 P.M. (Pacific Standard Time) on December 31, 1998.
4. The Board of Directors of the Corporation duly adopted the following resolutions on the 14th day of December, 1998:

RESOLVED, that the Corporation merge Pacific Vision Limited, Inc., its wholly-owned subsidiary corporation, into itself and assume all of Pacific Vision Limited, Inc.'s liabilities and obligations pursuant to Section 1110 of the General Corporation Law of the State of California ("GCLC") and Section 253 of the General Corporation Law of the State of Delaware ("GCLD") and does hereby assume all the liabilities of Pacific Vision Limited, Inc.;

RESOLVED FURTHER, that Pacific Vision Limited, Inc. shall be the disappearing corporation upon the effective date of the merger, which for purposes of the GCLC and the GCLD shall be 11:59 P.M. (Pacific Standard Time) on December 31, 1998, and the Corporation shall continue its existence as the surviving corporation pursuant to the provisions of the GCLC;

RESOLVED FURTHER, that the issued shares of Pacific Vision Limited, Inc. shall not be converted in any manner, nor shall any cash or other consideration be paid or delivered therefor, inasmuch as the Corporation is the owner of all outstanding shares of Pacific Vision Limited, Inc., but each said share which is issued as of the effective date of the merger shall be surrendered and canceled;

RESOLVED FURTHER, that the President and the Secretary be, and they hereby are, authorized and directed to execute, acknowledge and deliver certificates of ownership setting forth a copy of the resolution to merge said Pacific Vision Limited, Inc. and assume its liabilities and obligations, and the date of adoption thereof, and to file the same in the office of the Secretary of State of the State of Delaware and the office of the Secretary of State of the State of California; and

RESOLVED FURTHER, that the officers of the Corporation be, and each of them hereby is, authorized and directed to execute, acknowledge, deliver, certify, file and record such agreements, forms, deeds, bills, notes, certificates, instruments and other documents, and to make such arrangements, and do and perform all such acts and things as such officers, or any of them, may deem necessary, appropriate or desirable in order to consummate such merger.


We further declare under penalty of perjury under the laws of the State of California that the matters set forth in this certificate are true and correct of our own knowledge.

Dated: December 14, 1998.

By


F. Michael Ball, President

By


Francis R. Tunney, Jr., Secretary



State of Delaware
Office of the Secretary of State PAGE 1


I, EDWARD J. FREEL, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"PACIFIC VISION LIMITED, INC.", A DELAWARE CORPORATION, WITH AND INTO "ALLERGAN SALES, INC." UNDER THE NAME OF "ALLERGAN SALES, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF CALIFORNIA, AS RECEIVED AND FILED IN THIS OFFICE THE FIFTEENTH DAY OF DECEMBER, A.D. 1998, AT 9 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF OWNERSHIP IS THE THIRTY-FIRST DAY OF DECEMBER, A.D. 1998.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.




Edward J. Freel, Secretary of State

AUTHENTICATION: 9464669

DATE: 12-15-98

2979641 8100M

001484014

CERTIFICATE OF OWNERSHIP

MERGING

PACIFIC VISION LIMITED, INC.

INTO

ALLERGAN SALES, INC.

It is hereby certified as follows:

1. Allergan Sales, Inc. (the "Corporation") is a business corporation of the State of California.
2. The Corporation owns one hundred percent (100%) of the capital stock of Pacific Vision Limited, Inc., a corporation organized under the General Corporation Law of the State of Delaware.
3. The laws of the jurisdiction of organization of Allergan Sales, Inc. permit the merger of a business corporation of that jurisdiction with the business corporation of another jurisdiction.
4. The Corporation hereby merges Pacific Vision Limited, Inc. into the Corporation, effective as of 11:59 P.M. (Pacific Standard Time) on December 31, 1998.
5. The following is a copy of the resolutions duly adopted by the Board of Directors of the Corporation on the 14th day of December, 1998 to merge the said Pacific Vision Limited, Inc. into the Corporation:

RESOLVED, that the Corporation merge Pacific Vision Limited, Inc., its wholly-owned subsidiary corporation, into itself and assume all of Pacific Vision Limited, Inc.'s liabilities and obligations pursuant to Section 1110 of the General Corporation Law of the State of California ("GCLC") and Section 253 of the General Corporation Law of the State of Delaware ("GCLD") and does hereby assume all the liabilities of Pacific Vision Limited, Inc.;

RESOLVED FURTHER, that Pacific Vision Limited, Inc. shall be the disappearing corporation upon the effective date of the merger, which for purposes of the GCLC and the GCLD shall be 11:59 P.M. (Pacific Standard Time) on December 31, 1998, and the Corporation shall continue its existence as the surviving corporation pursuant to the provisions of the GCLC;

RESOLVED FURTHER, that the issued shares of Pacific Vision Limited, Inc. shall not be converted in any manner, nor shall any cash or other consideration be

paid or delivered therefor, inasmuch as the Corporation is the owner of all outstanding shares of Pacific Vision Limited, Inc., but each said share which is issued as of the effective date of the merger shall be surrendered and canceled;

RESOLVED FURTHER, that the President and the Secretary be, and they hereby are, authorized and directed to execute, acknowledge and deliver certificates of ownership setting forth a copy of the resolution to merge said Pacific Vision Limited, Inc. and assume its liabilities and obligations, and the date of adoption thereof, and to file the same in the office of the Secretary of State of the State of Delaware and the office of the Secretary of State of the State of California; and

RESOLVED FURTHER, that the officers of the Corporation be, and each of them hereby is, authorized and directed to execute, acknowledge, deliver, certify, file and record such agreements, forms, deeds, bills, notes, certificates, instruments and other documents, and to make such arrangements, and do and perform all such acts and things as such officers, or any of them, may deem necessary, appropriate or desirable in order to consummate such merger.

6. The surviving corporation in the Merger herein certified hereby agrees that it may be served with process in the State of Delaware in any proceeding for the enforcement of any obligation of Pacific Vision Limited, Inc., and for the enforcement of any obligation arising from the merger herein certified, including the rights of any dissenting stockholders thereof, and hereby irrevocably appoints the Secretary of State of the State of Delaware as its agent for service of process in any such suit or other proceedings and agrees that service of any such process may be made by personally delivering to and leaving with such Secretary of State of the State of Delaware duplicate copies of such process; and hereby authorizes the Secretary of State of the State of Delaware to send forthwith by registered mail one of such duplicate copies of such process addressed to said surviving corporation at 2525 Dupont Drive, Irvine, CA 92612, Attention: General Counsel unless said surviving corporation shall hereafter designate in writing to the Secretary of State of the State of Delaware a different address for such process, in which case the duplicate copy of such process shall be mailed to the last address so designated.

IN WITNESS WHEREOF, said Corporation has caused this Certificate to be signed by its authorized officers this 14th day of December, 1998.

By


F. Michael Ball, President

By


Francis R. Tunney, Jr., Secretary

Exhibit B

merger of VPLP
General partner into
Allergan Sales, Inc.
California / Delaware



SECRETARY OF STATE

I, **BILL JONES**, Secretary of State of the State of California,
hereby certify:


That the attached transcript of 2 page(s) has
been compared with the record on file in this office, of
which it purports to be a copy, and that it is full, true
and correct.

IN WITNESS WHEREOF, I execute this
certificate and affix the Great Seal of
the State of California this day of

DEC 29 1998

Bill Jones

Secretary of State



A518404

ENDORSED
FILED
In the office of the Secretary of State
of the State of California

CERTIFICATE OF OWNERSHIP

MERGING

ALLERGAN GENERAL, INC.

INTO

ALLERGAN SALES, INC.

DEC 15 1998

Bill Jones
BILL JONES, Secretary of State

F. Michael Ball and Francis R. Tunney, Jr. hereby certify that:

1. They are the president and secretary, respectively, of Allergan Sales, Inc., a California corporation (the "Corporation").
2. The Corporation owns one hundred percent (100%) of the outstanding shares of Allergan General, Inc., a Delaware corporation.
3. The Corporation hereby merges Allergan General, Inc. into the Corporation, effective for purposes of the General Corporation Law of the State of Delaware and the General Corporation Law of the State of California at 11:59 P.M. (Pacific Standard Time) on December 31, 1998.
4. The Board of Directors of the Corporation duly adopted the following resolutions on the 14th day of December, 1998:

RESOLVED, that the Corporation merge Allergan General, Inc., its wholly-owned subsidiary corporation, into itself and assume all of Allergan General, Inc.'s liabilities and obligations pursuant to Section 1110 of the General Corporation Law of the State of California ("GCLC") and Section 253 of the General Corporation Law of the State of Delaware ("GCLD") and does hereby assume all the liabilities of Allergan General, Inc.;

RESOLVED FURTHER, that Allergan General, Inc. shall be the disappearing corporation upon the effective date of the merger, which for purposes of the GCLC and the GCLD shall be 11:59 P.M. (Pacific Standard Time) on December 31, 1998, and the Corporation shall continue its existence as the surviving corporation pursuant to the provisions of the GCLC;


RESOLVED FURTHER, that the issued shares of Allergan General, Inc. shall not be converted in any manner, nor shall any cash or other consideration be paid or delivered therefor, inasmuch as the Corporation is the owner of all outstanding shares of Allergan General, Inc., but each said share which is issued as of the effective date of the merger shall be surrendered and canceled;


RESOLVED FURTHER, that the President and the Secretary be, and they hereby are, authorized and directed to execute, acknowledge and deliver certificates of ownership setting forth a copy of the resolution to merge said Allergan General, Inc. and assume its liabilities and obligations, and the date of adoption thereof, and to file the same in the office of the Secretary of State of the State of Delaware and the office of the Secretary of State of the State of California; and

RESOLVED FURTHER, that the officers of the Corporation be, and each of them hereby is, authorized and directed to execute, acknowledge, deliver, certify, file and record such agreements, forms, deeds, bills, notes, certificates, instruments and other documents, and to make such arrangements, and do and perform all such acts and things as such officers, or any of them, may deem necessary, appropriate or desirable in order to consummate such merger.

We further declare under penalty of perjury under the laws of the State of California that the matters set forth in this certificate are true and correct of our own knowledge.

Dated: December 14, 1998.

By 
F. Michael Ball, President

By 
Francis R. Tunney, Jr., Secretary



State of Delaware
Office of the Secretary of State PAGE 1


I, EDWARD J. FREEL, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"ALLERGAN GENERAL, INC.", A DELAWARE CORPORATION,
WITH AND INTO "ALLERGAN SALES, INC." UNDER THE NAME OF
"ALLERGAN SALES, INC.", A CORPORATION ORGANIZED AND EXISTING
UNDER THE LAWS OF THE STATE OF CALIFORNIA, AS RECEIVED AND FILED
IN THIS OFFICE THE FIFTEENTH DAY OF DECEMBER, A.D. 1998, AT 9
O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF
THE AFORESAID CERTIFICATE OF OWNERSHIP IS THE THIRTY-FIRST DAY
OF DECEMBER, A.D. 1998.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE
NEW CASTLE COUNTY RECORDER OF DEEDS.




Edward J. Freel, Secretary of State

2982378 8100M

AUTHENTICATION: 9477600

001484017

DATE: 12-21-98

CERTIFICATE OF OWNERSHIP

MERGING

ALLERGAN GENERAL, INC.

INTO

ALLERGAN SALES, INC.

It is hereby certified as follows:

1. Allergan Sales, Inc. (the "Corporation") is a business corporation of the State of California.
2. The Corporation owns one hundred percent (100%) of the capital stock of Allergan General, Inc., a corporation organized under the General Corporation Law of the State of Delaware.
3. The laws of the jurisdiction of organization of Allergan Sales, Inc. permit the merger of a business corporation of that jurisdiction with the business corporation of another jurisdiction.
4. The Corporation hereby merges Allergan General, Inc. into the Corporation, effective as of 11:59 P.M. (Pacific Standard Time) on December 31, 1998.
5. The following is a copy of the resolutions duly adopted by the Board of Directors of the Corporation on the 14th day of December, 1998 to merge the said Allergan General, Inc. into the Corporation:

RESOLVED, that the Corporation merge Allergan General, Inc., its wholly-owned subsidiary corporation, into itself and assume all of Allergan General, Inc.'s liabilities and obligations pursuant to Section 1110 of the General Corporation Law of the State of California ("GCLC") and Section 253 of the General Corporation Law of the State of Delaware ("GCLD") and does hereby assume all the liabilities of Allergan General, Inc.;

RESOLVED FURTHER, that Allergan General, Inc. shall be the disappearing corporation upon the effective date of the merger, which for purposes of the GCLC and the GCLD shall be 11:59 P.M. (Pacific Standard Time) on December 31, 1998, and the Corporation shall continue its existence as the surviving corporation pursuant to the provisions of the GCLC;

RESOLVED FURTHER, that the issued shares of Allergan General, Inc. shall not be converted in any manner, nor shall any cash or other consideration be paid

or delivered therefor, inasmuch as the Corporation is the owner of all outstanding shares of Allergan General, Inc., but each said share which is issued as of the effective date of the merger shall be surrendered and canceled;

RESOLVED FURTHER, that the President and the Secretary be, and they hereby are, authorized and directed to execute, acknowledge and deliver certificates of ownership setting forth a copy of the resolution to merge said Allergan General, Inc. and assume its liabilities and obligations, and the date of adoption thereof, and to file the same in the office of the Secretary of State of the State of Delaware and the office of the Secretary of State of the State of California; and

RESOLVED FURTHER, that the officers of the Corporation be, and each of them hereby is, authorized and directed to execute, acknowledge, deliver, certify, file and record such agreements, forms, deeds, bills, notes, certificates, instruments and other documents, and to make such arrangements, and do and perform all such acts and things as such officers, or any of them, may deem necessary, appropriate or desirable in order to consummate such merger.

6. The surviving corporation in the Merger herein certified hereby agrees that it may be served with process in the State of Delaware in any proceeding for the enforcement of any obligation of Allergan General, Inc., and for the enforcement of any obligation arising from the merger herein certified, including the rights of any dissenting stockholders thereof, and hereby irrevocably appoints the Secretary of State of the State of Delaware as its agent for service of process in any such suit or other proceedings and agrees that service of any such process may be made by personally delivering to and leaving with such Secretary of State of the State of Delaware duplicate copies of such process; and hereby authorizes the Secretary of State of the State of Delaware to send forthwith by registered mail one of such duplicate copies of such process addressed to said surviving corporation at 2525 Dupont Drive, Irvine, CA 92612, Attention: General Counsel, unless said surviving corporation shall hereafter designate in writing to the Secretary of State of the State of Delaware a different address for such process, in which case the duplicate copy of such process shall be mailed to the last address so designated.

IN WITNESS WHEREOF, said Corporation has caused this Certificate to be signed by its authorized officers this 14th day of December, 1998.

By


F. Michael Ball, President

By


Francis R. Tunney, Jr., Secretary

Corporations Section
P.O. Box 13697
Austin, Texas 78711-3697



Alberto R. Gonzales
Secretary of State

Office of the Secretary of State

Exhibit C

ENTITY:

VISION PHARMACEUTICALS L.P.

FILE NUMBER:

80863-10

DOCUMENT FILED:

CERTIFICATE OF CANCELLATION OF LIMITED PARTNERSHIP

FILED: DECEMBER 16, 1998

EFFECTIVE: DECEMBER 31, 1998 11:59 P.M.

This letter will acknowledge the receipt and filing of the above referenced document. The relevant statutory provision does not provide for a certificate of filing for this type of document and, therefore, this letter may be used as evidence of filing.

Corporations Section
Statutory Filings Division
512-463-5581

*Board action of allargen
Sales Inc. advised
this is the last time of
General and limited
partners and agrees
to cancel VLP.*

FILED
In the Office of the
Secretary of State of Texas

DEC 16 1998

Certificate of Cancellation
of Domestic Limited Partnership
Vision Pharmaceuticals L.P.

Corporation Section

The undersigned party hereby duly executes this Certificate of Cancellation of Domestic Limited Partnership (the "Certificate of Cancellation") of Vision Pharmaceuticals L.P., a Texas limited partnership (the "Limited Partnership"), which is being filed with the Secretary of State of the State of Texas in accordance with Sections 2.03 and 9.06 of the Texas Revised Limited Partnership Act.


1. The name of the Limited Partnership is Vision Pharmaceuticals L.P.
2. The Limited Partnership was formed under the laws of the State of Texas.
3. The date of filing of its Certificate of Limited Partnership was April 19, 1995, and the file number assigned to the Limited Partnership was 00080863-10.
4. The Certificate of Limited Partnership of Vision Pharmaceuticals L.P. is canceled upon the effectiveness of the mergers of each of its two existing partners into Allergan Sales, Inc., a California corporation.
5. The cancellation is to be effective as of 11:59 P.M. (PST) on December 31, 1998.

Dated this 14th day of December, 1998.

General Partner

Allergan Sales, Inc., a California corporation, as
successor to Allergan General, Inc., a Delaware
corporation

By



F. Michael Ball, President

Exhibit D

Delaware


The First State

merger of Allergan
Sales, Inc. into
Allergan Sales, LLC
in Delaware

6/3/2002

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF
DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT
COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"ALLERGAN SALES, INC.", A CALIFORNIA CORPORATION,
WITH AND INTO "ALLERGAN SALES, LLC" UNDER THE NAME OF
"ALLERGAN SALES, LLC", A LIMITED LIABILITY COMPANY ORGANIZED AND
EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED
AND FILED IN THIS OFFICE THE THIRD DAY OF JUNE, A.D. 2002, AT 9
O'CLOCK A.M.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

3496059 8100M

020354968

AUTHENTICATION: 1809761

DATE: 06-03-02

**CERTIFICATE OF MERGER
OF
ALLERGAN SALES, INC.
(a California corporation)
WITH AND INTO
ALLERGAN SALES, LLC
(a Delaware limited liability company)**

**(Pursuant to Section 18-209 of the
Delaware Limited Liability Company Act)**

Pursuant to the provisions of Section 18-209 of the Delaware Limited Liability Company Act ("DLLCA"), the undersigned surviving limited liability company submits the following Certificate of Merger for filing and certifies that:

FIRST: The name and jurisdiction of formation or incorporation of the limited liability company and corporation which are parties to the merger (the "constituent entities") are as follows:

Name of Entity

Allergan Sales, Inc.

Allergan Sales, LLC

State of Formation or Incorporation

California

Delaware

SECOND: An Agreement and Plan of Merger (the "Merger Agreement") between the constituent entities has been approved and executed by each of the constituent entities which are to merge in accordance with the requirements of Section 18-209 of the DLLCA.

THIRD: The name of the surviving limited liability company is: Allergan Sales, LLC (the "Surviving Entity").

FOURTH: The merger shall become effective upon filing of this Certificate of Merger.

FIFTH: The executed Merger Agreement is on file at the office of the Surviving Entity, the address of which is 2525 Dupont Drive, Irvine, California 92612.


SIXTH: A copy of the Merger Agreement will be furnished by the Surviving Entity, on request and without cost, to any member of the Surviving Entity or to any person holding an interest in the entity which is to merge with and into the Surviving Entity.

**STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:00 AM 06/03/2002
020354968 - 3496059**

IN WITNESS WHEREOF, this Certificate of Merger has been duly executed as of the 3rd day of June, 2002, and is being filed in accordance with Section 18-209 of the DLLCA by a duly authorized person on behalf of Allergan Sales, LLC.

ALLERGAN SALES, LLC,
a Delaware limited liability company

ALLERGAN, INC.,
a Delaware corporation,
its sole member

By: 


Name: Matthew J. Maletta

Title: Assistant Secretary

00678567

Merger of Allergan
Sales, Inc. into
Allergan Sales, LLC
in California

6/3/2002



SECRETARY OF STATE

I, **BILL JONES**, Secretary of State of the State of California,
hereby certify:

That the attached transcript of 1 page(s) has
been compared with the record on file in this office, of
which it purports to be a copy, and that it is full, true
and correct.

IN WITNESS WHEREOF, I execute this
certificate and affix the Great Seal of
the State of California this day of

JUN 18 2002

Bill Jones

Secretary of State

00678567

END RECD - FILED
in the office of the Secretary of State
of the State of California

JUN - 3 2002

BILL JONES, Secretary of State

AGREEMENT AND PLAN OF MERGER

BETWEEN

ALLERGAN SALES, INC.
(a California corporation)

AND

ALLERGAN SALES, LLC
(a Delaware limited liability company)

THIS AGREEMENT AND PLAN OF MERGER is made as of June 3, 2002 (this "Agreement of Merger"), by and between Allergan Sales, Inc., a California corporation (the "Corporation"), and Allergan Sales, LLC, a Delaware limited liability company (the "LLC", and collectively with the Corporation the "Constituent Companies").

WHEREAS, the Corporation was incorporated by the filing of Articles of Incorporation with the Secretary of State of the State of California on March 20, 1980; and

WHEREAS, the LLC was formed by the filing of a Certificate of Formation with the Secretary of State of the State of Delaware on February 25, 2002, and Allergan, Inc., a Delaware corporation and the sole member of the LLC (the "Member"), has entered into a Limited Liability Company Agreement dated as of February 25, 2002 (the "Operating Agreement");

NOW, THEREFORE, the parties hereby agree as follows:

1. Upon the terms and subject to the conditions hereof and in accordance with the California General Corporation Law (the "CGCL") and the Delaware Limited Liability Company Act (the "DLLCA"), the Corporation shall be merged with and into the LLC (the "Merger") at the Effective Time (as hereinafter defined). Following the Merger, the separate existence of the Corporation shall cease, and the LLC shall continue as the surviving entity (the "Surviving Entity") and shall succeed to and assume all of the rights and obligations of the Corporation in accordance with the CGCL and the DLLCA.

2. The parties hereto shall cause the Merger to be consummated by filing this Agreement of Merger, along with a Certificate of Merger, with the Secretary of State of the State of California pursuant to Section 1113 of the CGCL, and by filing a Certificate of Merger (the "Certificate of Merger") with respect thereto with the Secretary of State of the State of Delaware pursuant to Section 18-209 of the DLLCA. When used in this Agreement of Merger, the term "Effective Date" shall mean the date of filing of the Certificate of Merger with the Secretary of State of the State of Delaware.

3. The Merger shall have the effects set forth in Section 1113(i) of the CGCL and Section 18-209(g) of the DLLCA. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, except as otherwise provided herein, all of the property,

rights, privileges, powers and franchises of the Corporation and the LLC shall rest in the Surviving Entity, and all debts, liabilities and duties of the Corporation and the LLC shall become the debts, liabilities and duties of the Surviving Entity.

4. As of the Effective Time, by virtue of the Merger and without any action on the part of the Member of the LLC, or the shareholders or the Board of Directors of the Corporation, each share of capital stock in the Corporation issued and outstanding immediately prior to the Effective Time shall be canceled and extinguished without consideration. The membership interests of the LLC outstanding immediately prior to the Effective Time shall continue to be outstanding and shall not be affected by the Merger.

5. If, at any time after the Effective Time, the Surviving Entity shall consider or be advised that any deeds, bills of sale, assignments or assurances or any other acts or things are necessary, desirable or proper (a) to vest, perfect or confirm, of record or otherwise, in the Surviving Entity, its right, title or interest in, to or under any of the rights, privileges, powers, franchises, properties or assets of either of the Constituent Companies, or (b) otherwise to carry out the purposes of this Agreement of Merger, the Surviving Entity and its proper authorized representatives shall be authorized to execute and deliver, in the name and on behalf of either of the Constituent Companies, all such deeds, bills of sale, assignments and assurances and do, in the name and on behalf of each of the Constituent Companies, all such other acts and things necessary, desirable or proper to vest, perfect or confirm its right, title or interest in, to or under any of the rights, privileges, powers, franchises, properties or assets of such constituent Company and otherwise to carry out the purposes of this Agreement of Merger.

6. As required by the CGCL, the Surviving Entity hereby agrees to (i) be served in the State of California in any proceeding for the enforcement of an obligation of any Constituent Company and in any proceeding to enforce the rights of any holder of a dissenting interest or dissenting shares in a constituent domestic limited liability company or domestic other business entity; (ii) irrevocably appoint the Secretary of State of the State of California as its agent for service of process, which process may be forwarded to 2525 Dupont Drive, Irvine, California 92612; and (iii) promptly pay the holder of any dissenting interest or dissenting share in a constituent domestic limited liability company or domestic other business entity the amount to which that person is entitled under California law.

IN WITNESS WHEREOF, the undersigned have caused this Agreement of Merger to be executed by their respective officers or representatives thereunto duly authorized as of the date first above written.

ALLERGAN SALES, INC.,
a California corporation

By: 

Jeffrey L. Edwards
Vice President

By: 

Matthew J. Maletta
Assistant Secretary

ALLERGAN SALES, LLC,
a Delaware limited liability company

By: ALLERGAN, INC., its Sole Member

By: 

Name: Matthew J. Maletta

Title: Assistant Secretary

**CERTIFICATE OF APPROVAL
OF
AGREEMENT AND PLAN OF MERGER**

Jeffrey L. Edwards and Matthew J. Maletta state and certify that:

1. They are the Vice President and Assistant Secretary, respectively, of Allergan Sales, Inc., a California corporation.

2. The Agreement and Plan of Merger in the form attached was duly approved by the Board of Directors and the sole stockholder of the corporation.


3. There is only one class of shares and the total number of outstanding shares is 1,000 shares of Common Stock.


4. Approval of the Agreement and Plan of Merger by the holder of 100% of the outstanding shares of Common Stock was the vote required to approve the Agreement and Plan of Merger. The percentage of the outstanding shares of the corporation's shares entitled to vote on the Agreement of Merger which voted to approve the Agreement of Merger equaled the vote required.

5. No vote of the stockholders of the corporation's parent, Allergan, Inc., was required to approve the Agreement and Plan of Merger.

We further declare under penalty of perjury under the laws of the State of California that the matters set forth in this certificate are true and correct of our own knowledge.

Date: June 3, 2002


Jeffrey L. Edwards
Vice President


Matthew J. Maletta
Assistant Secretary



State of California
Bill Jones
Secretary of State

OTHER BUSINESS ENTITY
CERTIFICATE OF MERGER

(Corporations Code Sections 1113(g)(1) and (2), 6019.1, 8019.1 and 12540.1)

Filing Fee - Please see instructions.
IMPORTANT - Read instructions before completing this form.

This Space For Filing Use Only

1. Name of surviving entity: Allergan Sales, LLC	2. Type of entity: LLC	3. Secretary of State File Number: 200216110097	4. Jurisdiction: Delaware
5. Name of disappearing entity: Allergan Sales, Inc.	6. Type of entity: Corporation	7. Secretary of State File Number: C0978306	8. Jurisdiction: California
9. Future effective date, if any:		Day	Year

10. If a vote was required enter the outstanding interests of each class entitled to vote on the merger and the percentage of vote required:

Surviving Entity	Disappearing Entity
Each class entitled to vote	Each class entitled to vote
Percentage of vote required	Percentage of vote required
Sole Member	Sole Shareholder
100%	1,000 common shares issued 100%

11. The principal terms of the agreement of merger were approved by a vote of the number of interests or shares of each class that equaled or exceeded the vote required.

12. If equity securities of a parent party are to be issued in the merger:
[] No vote of the shareholders of the parent party was required. [] The required vote of the shareholders of the parent party was obtained.

SECTION 13 IS ONLY APPLICABLE IF THE SURVIVING ENTITY IS A DOMESTIC LIMITED LIABILITY COMPANY, DOMESTIC LIMITED PARTNERSHIP OR PARTNERSHIP.

13. Requisite changes to the information set forth in the Articles of Organization, Certificate of Limited Partnership or Statement of Partnership Authority of the surviving limited liability company, limited partnership or partnership resulting from the merger. Attach additional pages, if necessary.

SECTION 14 IS APPLICABLE IF THE SURVIVING ENTITY IS AN OTHER BUSINESS ENTITY.

14. Principal business address of the surviving other business entity:

Address: **2525 Dupont Drive**
City: **Irvine**

State: **California**

Zip: **92612**

15. Other information required to be stated in the Certificate of Merger by the laws under which each constituent other business entity is organized. Attach additional pages if necessary.

16. Statutory or other basis under which each foreign other business entity is authorized to effect the merger:
Delaware Limited Liability Company Act Section 18-209

17. Number of pages attached, if any: **1**

18. I certify that the statements contained in this document are true and correct of my own knowledge. I declare that I am the person who is executing this instrument, which execution is my act and deed.

See Attached
Signature of Authorized Person for the Surviving Entity Date
See Attached
Signature of Authorized Person for the Surviving Entity Date
See Attached
Signature of Authorized Person for the Disappearing Entity Date
See Attached
Signature of Authorized Person for the Disappearing Entity Date

Type or Print Name and Title of Person Signing Date
Type or Print Name and Title of Person Signing Date
Type or Print Name and Title of Person Signing Date
Type or Print Name and Title of Person Signing Date

For an entity that is a business trust, real estate investment trust or an unincorporated association, set forth the provision of law or other basis for the authority of the person signing.

FORM CBE Merger-1 - Approved by Secretary of State

ATTACHMENT PAGE
TO
OTHER BUSINESS ENTITY
CERTIFICATE OF MERGER

18. Signature of Authorized person for the Surviving Entity

Dated: June 3, 2002

ALLERGAN SALES, LLC,
a Delaware limited liability company

ALLERGAN, INC.,
a Delaware corporation,
its sole member

By: Matthew J. Maletta

Name: Matthew J. Maletta

Title: Assistant Secretary

Signature of Authorized person for the Disappearing Entity

Dated: June 3, 2002

ALLERGAN SALES, INC.,
a California corporation

By: Jeffrey L. Edwards

Name: Jeffrey L. Edwards

Title: Vice President

By: Matthew J. Maletta

Name: Matthew J. Maletta

Title: Assistant Secretary

